MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

380 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-27

Study Completion Date

2019-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compare the effect of paravertebral block (PVB) with Ropivacaine or placebo on the incidence of chronic pain 3 months after breast cancer surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chlorhydrate of Ropivacaine and Breast Cancer Surgery

NCT00370240

Breast Neoplasms Pain,Postoperative

COMPLETED PHASE4

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

NCT00542542

Breast Cancer

COMPLETED PHASE3

ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery

NCT04827030

Breast Surgery

COMPLETED PHASE4

Regional Anesthesia for Breast Surgery

NCT03941223

Breast Cancer

WITHDRAWN NA

Block REducing Pain After Surgery Trial

NCT03448913

Chronic Pain Post-Procedural

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before anesthesia, the second or third intercostal space is located. After an aspiration, 0.35 mL/kg of solution (ropivacaine 7.5 mg/mL or saline, maximum 30 mL) are injected into the paravertebral space. After 30 minutes, spread of PVB is evaluated by cold test on skin. Then, general anesthesia is induced.

Evaluation of the frequency of chronic pain at 3, 6 and 12 months by the Brief Pain Inventory (BPI) questionnaire and Neuropathic Pain Diagnostic (DN4) and Anxiety and depression evaluation by the Hospital Anxiety and Depression questionnaire (HAD) will be done.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Neoplasm of Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Saline (30 mL maximum)

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Ropivacaine

Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)

Group Type EXPERIMENTAL

Ropivacaine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline

Intervention Type DRUG

Ropivacaine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NA Cl 0.9% Naropeine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ treated by:

* either breast-conserving surgery with axillary lymph node dissection
* either radical surgery with or without axillary lymph node dissection.
2. 18 years ≤ Age ≥ 85 years.
3. ASA class 1, 2 or 3.
4. No analgesic treatment for 2 days (no pre-existing chronic pain)
5. If a biological control has been requested recently or deemed necessary by the Investigator, then it should be satisfactory : Adequate hematologic and hemostasis: neutrophil count (ANC) \> 1500/mm3, haemoglobin \> 9 g/dl and platelets \> 75 000/mm3, prothrombin time \> 70%, activated partial thromboplastin time \< 1.5 X Upper Limit of Normal (ULN)
6. Life expectancy ≥ 2 years.
7. Signed informed consent form.
8. Patient able to meet the self-assessments questionnaires (sufficient understanding assessments, proficiency in French)
9. Patient affiliated with a health insurance scheme (beneficiary or legal)

There is no prohibition for people to take part simultaneously in another search and there is no exclusion cause at the end of the research period.

Exclusion Criteria

1. Ongoing neoplasm or history of malignancy other than breast cancer with the exception of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has not relapsed during the 5 years preceding inclusion in the trial.
2. Bilateral breast carcinoma at the inclusion
3. Male subjects.
4. Metastatic breast carcinoma at diagnosis (M1).
5. Severe heart, liver and respiratory failure (ASA 4)
6. Allergy to local anesthetics and morphine.
7. Use of analgesics during the 48 hours preceding the surgical procedure.
8. History of breast surgery with painful sequelae
9. Major deformation of the spine
10. Puncture site infection
11. History of substance abuse.
12. Pregnant or lactating women, or women of childbearing potential without effective contraception
13. Subjects deprived of their liberty or under guardianship (including temporary guardianship).
14. Subjects unable to comply with medical follow-up of the trial for geographical, social or psychological reasons.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No